Advertisement

FDA Approves Clinolipid for Parenteral Nutrition to Alleviate Shortage — Physician’s First Watch

Medical News |
October 7, 2013

FDA Approves Clinolipid for Parenteral Nutrition to Alleviate Shortage

By Kristin J. Kelley

The FDA has approved a new lipid injectable emulsion (Clinolipid) to provide parenteral nutrition for adults who can't eat or drink. The mixture of refined olive and soybean oils was granted a priority review in order to resolve a product shortage.

Clinolipid is indicated for adults only — its label will include a warning against using it in preterm infants. Additionally, it should not be given to patients with serious hyperlipidemia disorders or to those with egg- or soybean-protein hypersensitivities, and it should be used cautiously in patients with liver disease or liver insufficiency. Side effects include abnormal liver function tests, elevated blood lipid levels, high blood sugar, nausea, and vomiting.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement